FRANKFURT, Germany — A genetically targeted cancer drug from Kura Oncology has helped put more patients’ advanced leukemias into remission, according to updated results from an ongoing clinical trial presented Sunday.
Based on data through April 12, seven of the 20 patients who received a daily dose of 600 milligrams of the company’s drug saw their cancer go into complete remission, a rate of 35%, according to findings presented here at the European Hematology Association’s annual meeting. The median duration of response for patients was 8.2 months.
Patients in the study had tried a median of three prior leukemia treatments.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect